Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Fallopian Tube Neoplasms 3Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Thymoma 1Solitary Fibrous Tumor, Pleural 1Sarcoma 1Neoplasms, Unknown Primary 1Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Mediastinal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liver Diseases 1Leukemia-Lymphoma, Adult T-Cell 1Congenital Abnormalities 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Brenner Tumor 1

Interventions

cediranib 3Pemetrexed 2pembrolizumab 1belinostat 1Watchful Waiting 1Platinum 1Pharmacogenomic Testing 1Dasatinib 1Cisplatin 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solitary Fibrous Tumor, Pleural × belinostat × Clear all
NCT00365053 2018-06-07

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
13 enrolled 7 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡